This morning we watched Novo Nordisk A/S drop -3.6% to a price of $132.0 per share. The Large-Cap Pharmaceutical company is now trading -12.28% below its average target price of $150.48. Analysts have set target prices ranging from $84.88 to $168.76 per share for Novo Nordisk A/S, and have given the stock an average rating of buy.
Novo Nordisk A/S's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 0.2%. The stock's short ratio is 1.25. At 0.0%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation.
Another number to watch is the company's rate of institutional share ownership, which now stands at 10.2%. In conclusion, we believe there is mixed market sentiment regarding Novo Nordisk A/S.
Institutions Invested in Novo Nordisk A/S
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-06-30 | Jennison Associates LLC | 1% | 21,220,641 | $2,801,124,612 |
| 2024-06-30 | FMR, LLC | 1% | 19,494,642 | $2,573,292,744 |
| 2024-06-30 | Morgan Stanley | 0% | 14,610,900 | $1,928,638,800 |
| 2024-06-30 | Bank of America Corporation | 0% | 14,189,363 | $1,872,995,916 |
| 2024-06-30 | Fisher Asset Management, LLC | 0% | 13,370,627 | $1,764,922,764 |
| 2024-06-30 | Sarofim, Fayez & Co | 0% | 12,552,088 | $1,656,875,616 |
| 2024-06-30 | Price (T.Rowe) Associates Inc | 0% | 9,503,764 | $1,254,496,848 |
| 2024-06-30 | Renaissance Technologies, LLC | 0% | 9,165,374 | $1,209,829,368 |
| 2024-06-30 | Folketrygdfondet | 0% | 8,838,723 | $1,166,711,436 |
| 2024-06-30 | Loomis Sayles & Company, LP | 0% | 8,897,437 | $1,174,461,684 |
